8,092 Results

Positive Phase III CELESTIAL study of Cabometyx in hepatocellular carcinoma (liver cancer)- Exelixis Inc.+ Ipsen.

 Added 21 hours ago

Exelixis, Inc. and Ipsen announced detailed results of the pivotal phase III CELESTIAL trial of cabozantinib in patients with previously...

FDA approves Riptide Aspiration System to treat Acute Ischemic Stroke ._ Medtronic.

 Added 21 hours ago

Medtronic plc announced that the company's Neurovascular business unit received FDA clearance of the Riptide Aspiration System, adding a valuable...

Patent Trial and Appeal Board invalidates Zytiga's 2027 patent and opens the way for generic competition.- Johnson & Johnson.

 Added 21 hours ago

. Johnson & Johnson's prostate cancer therapy Zytiga (abiraterone acetate) faces the prospect of generics this year- 2018-, as a...

European Commission approves MVASI the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.- Amgen + Allergan.

 Added 21 hours ago

Amgen and Allergan plc . announced that the European Commission (EC) has granted marketing authorization for MVASI (biosimilar bevacizumab). MVASI...

NICE rejects Xalkori for NHS use in ROS-1 positive non-small cell lung cancer.- Pfizer.

 Added 21 hours ago

In draft guidance, the National Institute for Health and Care Excellence (NICE) has not recommended Xalkori (crizotinib), from Pfizer, for...

NICE gives limited approval for Darzalex in multiple myeloma.- Janssen.

 Added 21 hours ago

The National Institute for Health and Care Excellence (NICE) has supported the NHS use of Darzalex (daratumumab), from Janssen, via...

Genetic variation and drug efficacy ‒ could this pave the way for personalised medicines?

 Added 21 hours ago

Genetic variation and drug efficacy ‒ could this pave the way for personalised medicines?

In this recent study published in the journal cell, researchers from the University of Copenhagen and the MRC Laboratory in Cambridge have attempted to measure the effect of genomic variations on drug pharmacodynamics.

CMR 2018

 Added 1 day ago

CMR 2018

The international Cardiovascular Magnetic Resonance (CMR) community will gather in Barcelona for CMR 2018

Ubenimex fails in LIBERTY study for pulmonary arterial hypertension and is discontinued for this condition.

 Added 1 day ago

Eiger BioPharmaceuticals, Inc. focused on the development and commercialization of targeted therapies for rare diseases, announced Phase II LIBERTY study...

Load more